astragaloside a has been researched along with Glial Cell Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J; Shen, X; Wang, S; Zhang, Y; Zhou, L | 1 |
| Huang, T; Li, B; Liu, N; Shen, W; Wang, F | 1 |
2 other study(ies) available for astragaloside a and Glial Cell Tumors
| Article | Year |
|---|---|
Astragaloside IV suppresses transforming growth factor-β1-induced epithelial-mesenchymal transition through inhibition of Wnt/β-catenin pathway in glioma U251 cells.
Topics: Antigens, CD; Apoptosis; beta Catenin; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Glioma; Humans; Saponins; Transforming Growth Factor beta1; Triterpenes; Wnt Signaling Pathway | 2020 |
Astragaloside IV inhibits progression of glioma via blocking MAPK/ERK signaling pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Glioma; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Saponins; Treatment Outcome; Triterpenes | 2017 |